✦ LIBER ✦

Monitoring of HBeAg levels may help to predict the outcomes of lamivudine therapy for HBeAg positive chronic hepatitis B

✍ Scribed by N. H. Park; J. W. Shin; J. H. Park; S-J. Bang; D-H. Kim; K. R. Joo; D. H. Kim

Book ID: 108885765
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 135 KB
Volume: 12
Category: Article
ISSN: 1352-0504
DOI: 10.1111/j.1365-2893.2005.00602.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of lamivudine re-treatment for

Efficacy of lamivudine re-treatment for relapsed patients after an initial lamivudine therapy in HBeAg-positive chronic hepatitis B

✍ J. W. Shin; N. H. Park; J. H. Park; J. H. Park; I. D. Jeong; S-J. Bang; K. R. Jo 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB

Combination of Lamivudine and adefovir t

Combination of Lamivudine and adefovir therapy in HBeAg-positive chronic hepatitis B patients with poor response to adefovir monotherapy

✍ L.-C. Wang; E.-Q. Chen; J. Cao; L. Liu; J.-R. Wang; B.-J. Lei; H. Tang 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB

Combination therapy of thymosin alpha-1

Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: A prospective randomized, comparative pilot study

✍ Hyun Woong Lee; Joung Il Lee; Soon Ho Um; Sang Hoon Ahn; Hye Young Chang; Yong K 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 188 KB

Results of up to 2 years of entecavir vs

Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B

✍ T.-T. Chang; Y.-C. Chao; V. V. Gorbakov; K.-h. Han; R. G. Gish; R. De Man; H. Ch 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB

Prediction of the response to peg-interf

Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment

✍ Bettina E. Hansen; Erik H.C.J. Buster; Ewout W. Steyerberg; Emmanuel Lesaffre; H 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

## Abstract Peginterferon (PEG‐IFN) results in HBeAg loss combined with virologic response in only a minority of patients with HBeAg positive chronic hepatitis B. Baseline predictors of response to PEG‐IFN include HBV‐genotype, pre‐treatment HBV DNA levels, and ALT. The aims of this study were to d

Early on-treatment prediction of respons

Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels

✍ Vincent Rijckborst; Bettina E. Hansen; Yilmaz Cakaloglu; Peter Ferenci; Fehmi Ta 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB 👁 2 views

Ferenci is a consultant for, advises, is on the speakers' bureau of, and received grants from Roche. Dr. Janssen is a consultant for and received grants from Roche, Bristol-Myers Squibb, Schering-Plough, Novartis, and Gilead. Dr. Flisiak received grants from Roche.